BioNTech SE (BNTX) Reports Q1 EPS of EUR14.24, Reiterates FY22 Guidance

BioNTech SE (NASDAQ: BNTX) reported Q1 EPS of EUR14.24. Revenue for the quarter came in at EUR6.4 billion.

The company reiterated COVID-19 2022 vaccine revenue guidance of €13 billion to €17 billion.

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Samsara Inc (IOT) Tops Q2 EPS by 4c, Beats on Revenue; Offers Q3 Guidance
• Torrid Holdings Inc. (CURV) Tops Q2 EPS by 8c; Offers Guidance